Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
J Virol ; 83(23): 12355-67, 2009 Dec.
Article in English | MEDLINE | ID: mdl-19793826

ABSTRACT

Antibodies against the extracellular virion (EV or EEV) form of vaccinia virus are an important component of protective immunity in animal models and likely contribute to the protection of immunized humans against poxviruses. Using fully human monoclonal antibodies (MAbs), we now have shown that the protective attributes of the human anti-B5 antibody response to the smallpox vaccine (vaccinia virus) are heavily dependent on effector functions. By switching Fc domains of a single MAb, we have definitively shown that neutralization in vitro--and protection in vivo in a mouse model--by the human anti-B5 immunoglobulin G MAbs is isotype dependent, thereby demonstrating that efficient protection by these antibodies is not simply dependent on binding an appropriate vaccinia virion antigen with high affinity but in fact requires antibody effector function. The complement components C3 and C1q, but not C5, were required for neutralization. We also have demonstrated that human MAbs against B5 can potently direct complement-dependent cytotoxicity of vaccinia virus-infected cells. Each of these results was then extended to the polyclonal human antibody response to the smallpox vaccine. A model is proposed to explain the mechanism of EV neutralization. Altogether these findings enhance our understanding of the central protective activities of smallpox vaccine-elicited antibodies in immunized humans.


Subject(s)
Antibodies, Monoclonal/immunology , Antibodies, Viral/immunology , Immunoglobulin Isotypes/immunology , Smallpox/prevention & control , Vaccinia virus/immunology , Viral Matrix Proteins/immunology , Animals , Body Weight , Complement C1q/immunology , Complement C3/immunology , Female , Humans , Mice , Mice, Inbred BALB C , Models, Biological , Neutralization Tests , Survival Analysis
2.
J Trace Elem Med Biol ; 23(2): 138-43, 2009.
Article in English | MEDLINE | ID: mdl-19398062

ABSTRACT

We evaluated the effects of acute high-dose sodium selenite (SEL) administration on the intestinal microcirculation and the release of the cytokines TNF-alpha, IL-1beta, IL-6 and IL-10 in experimental endotoxemia (induced by lipopolysaccharide-LPS). Three groups of animals (n=30) were studied: control group, endotoxemic group (15 mg kg(-1) i.v. LPS from E. coli) and SEL-treated LPS group (100 microg kg(-1) SEL i.v.). SEL treatment resulted in a significant reduced number of firmly adhering leukocytes in intestinal submucosal venules and reduced significantly the impairment of the intestinal functional capillary density. Despite of the improvement of microcirculatory parameters, we did not detect any changes in the pattern of cytokine release. In conclusion, administration of high-dose sodium SEL attenuates leukocyte adhesion and improves capillary perfusion within the intestinal microcirculation without affecting release of the cytokines TNF-alpha, IL-1beta, IL-6 and IL-10 in experimental endotoxemia.


Subject(s)
Cytokines/metabolism , Endotoxemia/metabolism , Intestines/blood supply , Sodium Selenite/administration & dosage , Animals , Cell Adhesion , Interleukin-10/metabolism , Interleukin-6/metabolism , Intestinal Mucosa/metabolism , Leukocytes/drug effects , Leukocytes/metabolism , Male , Microcirculation/drug effects , Rats , Rats, Inbred Lew , Sodium Selenite/pharmacology , Tumor Necrosis Factor-alpha/metabolism
3.
J Virol ; 83(3): 1201-15, 2009 Feb.
Article in English | MEDLINE | ID: mdl-19019965

ABSTRACT

Antibody neutralization is an important component of protective immunity against vaccinia virus (VACV). Two distinct virion forms, mature virion and enveloped virion (MV and EV, respectively), possess separate functions and nonoverlapping immunological properties. In this study we examined the mechanics of EV neutralization, focusing on EV protein B5 (also called B5R). We show that neutralization of EV is predominantly complement dependent. From a panel of high-affinity anti-B5 monoclonal antibodies (MAbs), the only potent neutralizer in vitro (90% at 535 ng/ml) was an immunoglobulin G2a (IgG2a), and neutralization was complement mediated. This MAb was the most protective in vivo against lethal intranasal VACV challenge. Further studies demonstrated that in vivo depletion of complement caused a >50% loss of anti-B5 IgG2a protection, directly establishing the importance of complement for protection against the EV form. However, the mechanism of protection is not sterilizing immunity via elimination of the inoculum as the viral inoculum consisted of a purified MV form. The prevention of illness in vivo indicated rapid control of infection. We further demonstrate that antibody-mediated killing of VACV-infected cells expressing surface B5 is a second protective mechanism provided by complement-fixing anti-B5 IgG. Cell killing was very efficient, and this effector function was highly isotype specific. These results indicate that anti-B5 antibody-directed cell lysis via complement is a powerful mechanism for clearance of infected cells, keeping poxvirus-infected cells from being invisible to humoral immune responses. These findings highlight the importance of multiple mechanisms of antibody-mediated protection against VACV and point to key immunobiological differences between MVs and EVs that impact the outcome of infection.


Subject(s)
Complement System Proteins/physiology , Vaccinia virus/immunology , Virion/immunology , Animals , Antibodies, Monoclonal/genetics , Antibodies, Monoclonal/immunology , Chlorocebus aethiops , Enzyme-Linked Immunosorbent Assay , Female , HeLa Cells , Humans , Mice , Mice, Inbred BALB C , Neutralization Tests , Recombinant Proteins/genetics , Recombinant Proteins/immunology , Vero Cells
4.
Immunol Res ; 34(3): 243-54, 2006.
Article in English | MEDLINE | ID: mdl-16891674

ABSTRACT

Although primary infection with human cytomegalovirus (HCMV), a beta-herpesvirus, is widespread and acquired early in life, it rarely causes disease in immune-competent individuals. However, in immune-compromised patients HCMV infection or reactivation invariably leads to serious disease, the effective treatment of which remains a difficult clinical problem. Current antiviral therapy is limited not only by toxicity but also by the continual emergence of drugresistant viruses. The limitations of these current therapeutics provides a strong impetus to develop novel approaches that will enhance the host's immune responsiveness while at the same time effectively controlling virus replication. Type I interferon (IFN) plays a critical role in initiating innate antiviral defenses and promoting adaptive responses and lymphotoxin (LT)-alphabeta has recently been identified as an essential effector cytokine regulating the induction of type I IFN during CMV infection. In particular, CMV infection of immune-compromised mice has revealed the immunotherapeutic potential of the lymphotoxin-beta receptor (LTbetaR) signaling pathway to restore immune function and provide protection from CMV mortality. In this review, we discuss the potential benefits and risks associated with LTbetaR-directed immunotherapy for CMV disease and other persistent viral infections.


Subject(s)
Cytomegalovirus Infections/immunology , Cytomegalovirus/immunology , Intracellular Signaling Peptides and Proteins/immunology , Lymphotoxin-alpha/immunology , Animals , Clinical Trials as Topic , Cytomegalovirus Infections/therapy , Female , Humans , Immunity, Innate/immunology , Infant, Newborn , Mice , Pregnancy
5.
J Immunol ; 174(11): 7217-25, 2005 Jun 01.
Article in English | MEDLINE | ID: mdl-15905567

ABSTRACT

The importance of lymphotoxin (LT) betaR (LTbetaR) as a regulator of lymphoid organogenesis is well established, but its role in host defense has yet to be fully defined. In this study, we report that mice deficient in LTbetaR signaling were highly susceptible to infection with murine CMV (MCMV) and early during infection exhibited a catastrophic loss of T and B lymphocytes, although the majority of lymphocytes were themselves not directly infected. Moreover, bone marrow chimeras revealed that lymphocyte survival required LTalpha expression by hemopoietic cells, independent of developmental defects in lymphoid tissue, whereas LTbetaR expression by both stromal and hemopoietic cells was needed to prevent apoptosis. The induction of IFN-beta was also severely impaired in MCMV-infected LTalpha(-/-) mice, but immunotherapy with an agonist LTbetaR Ab restored IFN-beta levels, prevented lymphocyte death, and enhanced the survival of these mice. IFN-alphabetaR(-/-) mice were also found to exhibit profound lymphocyte death during MCMV infection, thus providing a potential mechanistic link between type 1 IFN induction and lymphocyte survival through a LTalphabeta-dependent pathway important for MCMV host defense.


Subject(s)
Herpesviridae Infections/immunology , Herpesviridae Infections/pathology , Interferon-beta/physiology , Lymphocyte Subsets/immunology , Lymphocyte Subsets/pathology , Lymphotoxin-alpha/physiology , Membrane Proteins/physiology , Muromegalovirus/immunology , Animals , Apoptosis/genetics , Apoptosis/immunology , Cell Survival/immunology , Herpesviridae Infections/genetics , Herpesviridae Infections/mortality , Humans , Immunity, Cellular/genetics , Interferon-beta/biosynthesis , Lymphocyte Subsets/metabolism , Lymphopenia/genetics , Lymphopenia/immunology , Lymphopenia/pathology , Lymphotoxin beta Receptor , Lymphotoxin-alpha/deficiency , Lymphotoxin-alpha/genetics , Lymphotoxin-beta , Membrane Proteins/deficiency , Membrane Proteins/genetics , Mice , Mice, Inbred C57BL , Mice, Knockout , Mice, Transgenic , Receptor, Interferon alpha-beta , Receptors, Interferon/deficiency , Receptors, Interferon/genetics , Receptors, Interferon/physiology , Receptors, Tumor Necrosis Factor/deficiency , Receptors, Tumor Necrosis Factor/genetics , Receptors, Tumor Necrosis Factor/metabolism , Receptors, Tumor Necrosis Factor/physiology , Signal Transduction/genetics , Signal Transduction/immunology , Tumor Necrosis Factor Ligand Superfamily Member 14 , Tumor Necrosis Factor-alpha/deficiency , Tumor Necrosis Factor-alpha/genetics , Tumor Necrosis Factor-alpha/physiology
6.
Cytokine Growth Factor Rev ; 14(3-4): 289-96, 2003.
Article in English | MEDLINE | ID: mdl-12787566

ABSTRACT

LIGHT is a tumor necrosis factor (TNF) superfamily ligand that regulates T cell immune responses by signaling through the herpes virus entry mediator (HVEM) and the lymphotoxin beta receptor (LTbetaR). This review will present a summary of recent advances made regarding the immunobiology of the LIGHT-HVEM and LTbetaR systems. LIGHT has emerged as a potent initiator of T cell co-stimulation signals effecting CTL-mediated tumor rejection, allograft rejection and graft versus host disease. Constitutive expression of LIGHT leads to tissue destruction and autoimmune-like disease syndromes. In contrast to LTalphabeta, LIGHT plays a minimal role in lymphoid tissue development, yet some evidence indicates a role in negative selection in the thymus. These results provide an encouraging profile for the LIGHT-HVEM-LTbetaR axis as a potential target for controlling cellular immune reactions.


Subject(s)
Membrane Proteins/immunology , Receptors, Tumor Necrosis Factor/immunology , Receptors, Virus/immunology , T-Lymphocytes/immunology , Tumor Necrosis Factor-alpha/immunology , Animals , Dendritic Cells/immunology , Gene Expression , Graft Rejection/immunology , Graft vs Host Disease/prevention & control , Humans , Immunity, Cellular , Membrane Proteins/deficiency , Membrane Proteins/genetics , Mice , Mice, Knockout , Models, Immunological , Neoplasms/immunology , Receptors, Tumor Necrosis Factor/genetics , Receptors, Tumor Necrosis Factor, Member 14 , Receptors, Virus/genetics , Signal Transduction , Tumor Necrosis Factor Ligand Superfamily Member 14 , Tumor Necrosis Factor-alpha/deficiency , Tumor Necrosis Factor-alpha/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...